Wegovy and muscle mass: what actually happens when you lose weight on semaglutide

You're eating less than before — so what's happening to your muscle?

Picture this: you've been on Wegovy for eight weeks. Appetite is noticeably lower, portions are smaller, and the scale is moving. But a friend who lifts weights mentions they heard GLP-1 medicines eat through muscle. Now you're second-guessing the whole thing.

Here's the straightforward picture. When the body runs a sustained energy deficit (from any cause) it draws on stored fuel. Fat is the primary target, but lean tissue, including muscle, contributes too. This is basic metabolic physiology, not something unique to semaglutide. The proportion of weight lost as lean mass during active dieting typically sits somewhere between 20% and 40% depending on the individual, the size of the deficit, activity level and protein intake.

What the STEP 1 trial data showed, published in the New England Journal of Medicine, is that participants using semaglutide 2.4mg over 68 weeks lost around 15% of their body weight on average. The composition of that loss was predominantly fat mass. Lean mass did decrease in absolute terms, as it does with calorie restriction generally, but the ratio was not markedly different from what calorie restriction alone tends to produce. That finding matters, because it means the concern about semaglutide specifically targeting or accelerating muscle breakdown is not supported by the trial data.

That said, 15% body weight loss is substantial. If you start at 100 kg and lose 15 kg, even a relatively lean loss ratio still represents meaningful change in muscle mass in raw kilograms. This is why body composition (not just weight) is worth discussing with your prescriber.

What makes the difference: protein, resistance training, and pacing

The things that protect muscle during weight loss are well-established and none of them involve a magic supplement. Resistance exercise (anything that loads the muscles against a force, from weight machines to bodyweight work) sends the signal to maintain lean tissue even as overall energy intake drops. This effect is consistent across the literature and holds during GLP-1 treatment.

Protein intake matters too. When overall food volume falls because appetite is lower, there is a real risk of under-eating protein without realising it. On a reduced-calorie plan, current UK and international guidance generally suggests higher relative protein targets than the population average precisely because the body is more likely to draw on muscle when protein is scarce. The NHS Live Well healthy weight guidance covers some of this ground, though specific targets for people on GLP-1 treatment are best discussed with a prescriber or dietitian who knows your full picture.

Pacing is underrated. Faster weight loss tends to carry a higher proportion of lean mass reduction. The titration schedule built into Wegovy (starting low and stepping up gradually) is designed partly for tolerability, but the slower trajectory of loss it creates may also be gentler on body composition than crash dieting would be. Worth keeping in mind if you're ever tempted to rush ahead of the schedule.

For more on how semaglutide specifically interacts with muscle tissue, including what the mechanistic research suggests, that page goes deeper on the biology.

Older adults and people who train: when does this matter most?

Muscle mass naturally declines with age, sarcopenia is a recognised clinical concern from middle age onwards. For someone in their fifties or sixties using Wegovy, the question of muscle preservation carries more weight than it does for a 30-year-old. This does not mean the medicine is unsuitable; it means the conversation with a prescriber needs to factor it in explicitly.

Similarly, if you train seriously (competitive sport, powerlifting, endurance events) your relationship with muscle mass is different from the general population's. The appetite suppression that makes Wegovy effective for most people can make it genuinely difficult to eat enough protein and total calories to fuel training and recovery. These are not reasons to avoid treatment; they are reasons to go into it with a clear plan agreed with a clinician who understands your goals.

People considering the specific question of muscle loss on Wegovy and how significant it is in practice will find a detailed breakdown on that page. For the broader picture of how Wegovy works and who it is licensed for, the Wegovy overview covers eligibility, the titration pathway and what clinical supervision looks like in practice.

If cost is part of your thinking, the Wegovy pricing page sets out what private treatment actually costs in the UK and what a legitimate price should include.

The bottom line, and how a prescriber fits in

Semaglutide does not appear to cause muscle loss beyond what weight loss itself produces. That is reassuring, but it is not the end of the conversation. How much muscle you lose, whether it matters for your health or your sport, and what you can do to minimise it, all of that is personal. A prescriber reviewing your case can factor in your age, your activity, your protein habits, and any conditions that make lean mass preservation a clinical priority.

At nume, every consultation is read by a GPhC-registered prescriber, a real clinician reads your answers the same day, not software working through a checklist. If muscle mass is on your mind, say so in the consultation. It is exactly the kind of nuance that changes a recommendation.

You can also read about whether semaglutide affects muscle mass from a broader evidence perspective, or how much muscle is typically lost on Wegovy in practice. The semaglutide treatment page and our weight-loss treatment overview are good starting points if you want to compare your options before speaking to anyone.

When you're ready, speak to our prescribers through a free consultation, no waiting list, same-day clinical review.